NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model
Portfolio Pulse from Benzinga Newsdesk
NanoViricides reported that its lead antiviral agent NV-387 showed a desirable blood concentration profile in a non-human primate model, maintaining a stable concentration over 24 hours with a dose-dependent increase.
June 04, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoViricides' lead antiviral agent NV-387 demonstrated a stable blood concentration profile in a non-human primate model, which is a positive indicator for its efficacy and potential success in clinical trials.
The stable blood concentration profile of NV-387 in a non-human primate model suggests potential efficacy and success in future clinical trials, which is likely to positively impact NanoViricides' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100